Neuroscience clinical development is experiencing a surge in funding after nearly a decade of dropping rates. Big pharma companies like Acadia, Biogen, and Novartis are turning their investments towards these programs, and we’ve seen some recent notable successes in treatments for neurological diseases.
Read our article with the Journal for Clinical Studies to learn more about the success we are seeing and hear why we expect this uptick in funding will continue.
Authors:
Christine Moore, PhD
Vice President, Neuroscience, Scientific Solutions
Henry J. Riordan, PhD
Chief Development Officer
Natalia Drosopoulou, PhD
Vice President, Project Management, Neuroscience
